Allergan's $1.7 Billion Acquisition of Tobira for NASH Drug Sets 1750% Potential Premium on Can-Fite Stock #msg-125465359 Can-Fite also has Piclidenoson, headed into two Phase III trials addressing multi-billion dollar autoimmune disease markets, all for a market cap under $30 million. Can-Fite makes for a very attractive acquisition target.